TRACON Pharmaceuticals Inc (NASDAQ:TCON) does about 3.38M shares in volume on a normal day but saw 6849022 shares change hands in Monday trading. The company now has a market cap of 8.74M USD. Its current market price is $0.19, marking a decrease of -24.79% compared to the previous close of $0.26. The 52 week high reached by this stock is $2.14 whilst the lowest price level in 52 weeks is $0.13.
TRACON Pharmaceuticals Inc (TCON) has a 20-day trading average at $0.3813 and the current price is -91.03% off the 52-week high compared with 52.99% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.2687 and its 200-day simple moving average is $0.2337. If we look at the stock’s price movements over the week, volatility stands at 39.97%, which decreases to 31.75% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 38.41 to suggest the stock is neutral.
The consensus objective for the share price is $2.00, suggesting that the stock has a potential upside of 90.5% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on April 16, 2021 when BTIG Research upgraded the stock to “Buy” and issued a price target of $14. H.C. Wainwright reiterated its price target at $15-$18.
TRACON Pharmaceuticals Inc (TCON) stock is down -53.32% over the week and -17.42% over the past month. Its price is 9.65% year-to-date and -90.10% over the past year.
The stock last released its quarterly earnings report for quarter ended 12/30/2023, with the company’s earnings per share (EPS) of $0.01 above consensus estimates by $0.09. TCON’s earnings per share are forecast to shrink by -109.10% this year and 30.40% over next year.
To reach the target analysts have set, the stock logically needs to grow 90.5 percent from here.
Outstanding shares total 44.27M with insiders holding 2.59% of the shares and institutional holders owning 11.87% of the company’s common stock. The beta has a value of 1.09. Price to sales ratio is 0.73.
